Boston Scientific to acquire Penumbra for portfolio of vascular treatments
MLex Summary: Boston Scientific Corp. said it will acquire Penumbra Inc. in a cash and stock deal with an enterprise value of approximately $14.5 billion. The merger gives Boston Scientific entry into...To view the full article, register now.
Already a subscriber? Click here to view full article